[ad_1]
Beijing:
Around 50,000 individuals, throughout various nations, are collaborating in section 3 medical trials of a COVID vaccine developed by the China National Biotec Group (CNBG), the corporate stated on Saturday in a press launch.
“The third phase of clinical trials of the inactivated CNBG vaccine against COVID-19 is significantly accelerating, and clinical trials are already underway in several countries, including Bahrain, UAE, Morocco, Peru, Argentina, with about 50,000 people participating,” the CNGB stated.
Media reported in July that section 3 trial of CNBG’s vaccine can even be held in Uzbekistan, and Pakistan has expressed curiosity in conducting medical trials as nicely.
(Except for the headline, this story has not been edited by NDTV workers and is printed from a syndicated feed.)
[ad_2]
Source hyperlink